Among 2 analysts covering Tracsis PLC (LON:TRCS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tracsis PLC had 6 analyst reports since August 12, 2015 according to SRatingsIntel. Investec maintained the shares of TRCS in report on Wednesday, August 12 with “Buy” rating. The rating was maintained by Investec on Wednesday, December 2 with “Buy”. Investec maintained the stock with “Buy” rating in Wednesday, November 4 report. The firm has “Buy” rating given on Wednesday, November 4 by WH Ireland. The rating was maintained by Investec with “Buy” on Monday, September 28. The stock of Tracsis plc (LON:TRCS) earned “Buy” rating by Investec on Tuesday, February 16. See Tracsis plc (LON:TRCS) latest ratings:
Analysts expect Akcea Therapeutics, Inc. (NASDAQ:AKCA) to report $-0.20 EPS on February, 5.After having $-0.18 EPS previously, Akcea Therapeutics, Inc.’s analysts see 11.11% EPS growth. The stock increased 5.09% or $0.85 during the last trading session, reaching $17.55. About 404,589 shares traded or 29.76% up from the average. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since January 6, 2017 and is . It has underperformed by 16.70% the S&P500.
Tracsis plc, together with its subsidiaries, provides software development and consultancy services for the rail industry. The company has market cap of 143.67 million GBP. The firm operates through two divisions, Rail Technology and Services and Traffic & Data Services. It has a 39.53 P/E ratio. It offers activities and planning systems, which include rolling stock and crew planning and optimization tools; and information management and performance reporting software.
It closed at GBX 510 lastly. It is down 0.00% since January 6, 2017 and is . It has underperformed by 16.70% the S&P500.
Among 3 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 5 analyst reports since August 8, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, August 8 by BMO Capital Markets. Stifel Nicolaus initiated it with “Buy” rating and $1900 target in Tuesday, August 8 report. The company was maintained on Tuesday, October 31 by Stifel Nicolaus. On Tuesday, November 7 the stock rating was maintained by Stifel Nicolaus with “Buy”.
Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.17 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.